Technical Analysis for JANX - Janux Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing High | Bullish | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Up 3 Days in a Row | Strength | 0.00% | |
| Up 4 Days in a Row | Strength | 0.00% | |
| New 52 Week Closing High | Bullish | 2.09% | |
| Inside Day | Range Contraction | 2.09% | |
| Wide Bands | Range Expansion | 2.09% | |
| Up 3 Days in a Row | Strength | 2.09% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 15 hours ago |
| Possible Pocket Pivot | about 15 hours ago |
| Up 5% | about 16 hours ago |
| 60 Minute Opening Range Breakout | about 18 hours ago |
| Up 3% | about 18 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/10/2024
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Immunology Immune System Tumor Platform Technology Chimeric Antigen Receptor T Cell T Cell Clusters Of Differentiation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 61.0 |
| 52 Week Low | 5.65 |
| Average Volume | 1,213,952 |
| 200-Day Moving Average | 17.72 |
| 50-Day Moving Average | 41.42 |
| 20-Day Moving Average | 47.85 |
| 10-Day Moving Average | 51.02 |
| Average True Range | 4.26 |
| RSI (14) | 75.12 |
| ADX | 41.2 |
| +DI | 39.53 |
| -DI | 11.17 |
| Chandelier Exit (Long, 3 ATRs) | 48.21 |
| Chandelier Exit (Short, 3 ATRs) | 47.42 |
| Upper Bollinger Bands | 60.42 |
| Lower Bollinger Band | 35.28 |
| Percent B (%b) | 0.91 |
| BandWidth | 52.55 |
| MACD Line | 4.48 |
| MACD Signal Line | 3.95 |
| MACD Histogram | 0.5365 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 64.97 | ||||
| Resistance 3 (R3) | 64.84 | 62.44 | 63.84 | ||
| Resistance 2 (R2) | 62.44 | 60.72 | 62.51 | 63.46 | |
| Resistance 1 (R1) | 60.32 | 59.65 | 61.38 | 60.45 | 63.09 |
| Pivot Point | 57.92 | 57.92 | 58.46 | 57.99 | 57.92 |
| Support 1 (S1) | 55.80 | 56.20 | 56.86 | 55.93 | 53.29 |
| Support 2 (S2) | 53.40 | 55.13 | 53.47 | 52.92 | |
| Support 3 (S3) | 51.28 | 53.40 | 52.54 | ||
| Support 4 (S4) | 51.41 |
